 Cocrystal Pharma Inc NASDAQ: COCP announces that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed potent in vitro activity against the SARS-CoV-2 Delta IndiaB.1.617.2 and Gamma BrazilP.1 variants. Our next steps are to scale-up synthesis and manufacture active pharmaceutical ingredient API to support Investigational New Drug IND-enabling studies to advance CDI-45205 into clinical trials, said James Martin, CFO, and interim co-CEO. 